

TFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Dated: November 29, 2006 Signature: [Signature]
(Dawn Class)

Docket No.: GPCG-P01-297
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Caligiuri *et al.*

Confirmation No.: Not Yet Assigned

Application No.: 10/589,840

Art Unit: Not Yet Assigned

Filed: August 17, 2006

For: METHODS FOR TREATING RESISTANT
OR REFRACTORY TUMORS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. § 1.97(b)(3)).

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 C.F.R. § 1.98(a)(2).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as


defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. **18-1945**, under Order No. **GPCG-P01-297**.

Dated: November 29, 2006

Respectfully submitted,

By 
Yu Lu/Ph.D.

Registration No.: 50,306
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/589,840
				Filing Date	August 17, 2006
				First Named Inventor	Maureen Caligiuri
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	GPCG-P01-297


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	6,025,473	02-15-2000	Deeley et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO 04/105761 A1	12-09-2004	PHARMA MAR, S.A.U.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	C1	Beale et al., "Phase I study of oral JM216 given twice daily," Cancer Chemother Pharmacol., 42:142-148, (1998).				
	C2	Cmelak et al., "Phase I Study of JM-216 with Concurrent Radiation in Non-Small Cell Lung Cancer and Squamous Cell Head and Neck Cancer," Proc. ASCO, Vol 18, page 1, (1999).				
	C3	Fokkema et al., "Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients with Small-Cell Lung Cancer," Journal of Clinical Oncology, 17(12):3822-3827, (1999).				
	C4	George et al., "A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest," Investigational New Drugs, 19:303-310, (2001).				
	C5	Hoffman et al., "Oral JM-216 Plus Concomitant Radiotherapy (RT) for Patients (PTS) with Advanced Malignancies of the Chest," Proceedings of ASCO, Vol. 17, page 1, (1998).				
	C6	Jones et al., "Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies," Investigational New Drugs, 20:55-61, (2002).				
	C7	Judson et al., "Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer. An EORTC early clinical studies group investigation," Annals of Oncology, 8:604-606, (1997).				
	C8	Kelland et al., "Ammine/Amine Platinum (IV) Dicarboxylates: A Novel Class of Platinum Complex Exhibiting Selective Cytotoxicity to Intrinsically Cisplatin-resistant Human Ovarian Carcinoma Cell Lines," Cancer Research, 52:822-828, (1992).				
	C9	Kelland et al., "Relationships Between Resistance to Cisplatin and Antifolates in Sensitive and Resistant Tumour Cell Lines," European Journal of Cancer, 31A(6):981-986, (1995).				
	C10	Kurata et al., "Pharmacokinetic and Pharmacodynamic Analysis of Bis-acetato-amine-dichloro-cyclohexylamine-platinum (IV) (JM216) Administered Once a Day for Five Consecutive Days: A Phase I Study," Jpn J Clin Oncol., 30(9):377-384, (2000).				
	C11	Latif et al., "Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)," Investigational New Drugs, 23:79-84, (2005).				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/589,840		
		Filing Date	August 17, 2006		
		First Named Inventor	Maureen Caligiuri		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	GPCG-P01-297

	C12	McKeage et al., "Phase I and Pharmacokinetic Study of an Orally Administered Platinum (Pt) Complex (JM216) Using a Daily x 5 Administration Schedule," Proc. ASCO, Vol 13, page 1, (1994).	
	C13	McKeage, "Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents," Platinum-Based Drugs in Cancer Therapy, pages 251-275.	
	C14	Medina-Gundrum et al., "AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients," Anti-Cancer Drugs, 14(4):275-260, (2003).	
	C15	Mellish et al., "In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin," Br. J. Cancer, 68:240-250, (1993).	
	C16	Mellish et al., "Mechanisms of Acquired Resistance to the Orally Active Platinum-based Anticancer drug Bis-acetato-amine-dichloro-cyclohexylamine Platinum (IV) (JM216) in Two Human Ovarian Carcinoma Cell Lines," Cancer Research, 54:6194-6200, (1994).	
	C17	Orr et al., "Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin," Br. J. Cancer 70:415-420, (1994).	
	C18	Peereboom et al., "Phase II Trial of Oral Platinum (JM-215) in Hormone Refractory Prostate Cancer (HRPC)," Proceedings of ASCO, Vol. 17, page 1, (1998).	
	C19	Plasencia et al., "Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines," Investigational New Drugs, 22:399-409, (2004).	
	C20	Raynaud et al., "Biotransformation of the platinum drug JM216 following oral administration to cancer patients," Cancer Chemother Pharmacol., 38:155-162, (1996).	
	C21	Sessa et al., "Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days," Annals of Oncology, 9:1315-1322, (1998).	
	C22	Sharp et al., "Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines," British Journal of Cancer, 78(2):175-180, (1998).	
	C23	Smith, "Chemotherapy for Hormone Refractory Prostate Cancer," Hormone Refractory Prostate Cancer, 26(2):323-331, (1999).	
	C24	Soulie et al., "Oxaliplatin/cisplatin (L-OHP/CDDP) Combination in Heavily Pretreated Ovarian Cancer," European Journal of Cancer, 33(9):1400-1406, (1997).	
	C25	Sternberg et al., "Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer," Oncology, 68:2-9, (2005).	
	C26	Sternberg, "Satraplatin in the treatment of hormone-refractory prostate cancer," BJU International, 96:990-994, (2005).	
	C27	Twentyman et al., "Sensitivity to Novel Platinum Compounds of Panels of Human Lung Cancer Cell Lines with Acquired and Inherent Resistance to Cisplatin," Cancer Research, 52:5674-5680, (1992).	
	C28	Vouillamoz-Lorenz et al., "Pharmacokinetics of Satraplatin (JM216), an Oral Platinum (IV) Complex under Daily Oral Administration for 5 or 14 Days," Anticancer Research, 23:2757-2766, (2003).	
	C29	Zeilek et al., "Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients," Journal of Clinical Oncology, 20(10):2551-2558, (2002).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--